Irodalom:
1. Ajani JA, Randolph Hecht J, HO L. et al: An open-label, multinational, multicenter study of G17DT
vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or
gastroesophageal cancer: the GC4 study. Cancer. 2006 May 1; 106 (9):1908-16.
2. Back JH, Kim JG, Jeon SB. et al: Phase II study of capecitabine and irinotecan combination chemotherapy
in patients with advanced gastric cancer. Br J Cancer. 2006 May 22;94 (10):1407-11.
3. Becker JC, Muller-Tidow C, Stolte M. et al: Acetylsalicylic acid enhances antiproliferative effects of
the EGFR inhibitor in the absence of ativating mutations in gastric cancer. Int J Oncol 2006. Sep; 29
(3):615-23.
4. Beghelli S, de Manzoni G, Barbi S. et al: Microsatellite instability in gastric cancer is associated with
better prognosis in only stage II cancers. Surgery. 2006 Mar; 139 (3):347-56.
5. Cayanna L, Artioli F, Codignola C. et al: Oxaliplatin in combination with 5-fluorouracil (5-FU) and
leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol. 2006 Aug;
29 (4):371-5.
6. Chandanos E, Lindblad M, Jia C. et al: Tamoxifen exposure and risk of oesophageal and gastric
adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer.
A gyomor 133
2006 Jul 3;95 (1):118-22.
7. Chao Y, Li CP, Chao TY. et al: An open, multi-centre, phase II clinical trial to evaluate the efficacy and
safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. Br J Cancer. 2006
Jul 17; 95 (2):159-63.
8. Cho BC, Kim JH, Kim CB et al: Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination
chemotherapy for metastatic gastric cancer. Oncol Rep. 2006 Mar; 15 (3):621-7.
9. Dipetrillo T, Milas L, Evans D. et al: Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for
esophageal and gastric cancer: a phase I study. Am J Clin Oncol. 2006 Aug; 29 (4):376-9.
10. Fall K, Ye W, Nyren O: Antibiotic treatment and risk of gastric cancer. Gut. 2006 Jun; 55 (6):793-6.
11. Hironaka S, Zenda S, Boku N. et al: Weekly paclitaxel as second-line chemotherapy for advanced or
recurrent gastric cancer. Gastric Cancer. 2006;9 (1):14-8.
12. Ieung HC, Rha SY, Kim YT. et al: A phase II study of infusional 5-fluorouracil and low-dose leucovorin
with docetaxel for advanced gastric cancer. Oncology. 2006;70 (1):63-70.
13. Inokochi M, Yamashita T, Yamada H. et al: Phase I/II study of S-1 combined with irinotecan for
metastatic advanced gastric cancer. Br J Cancer. 2006 Apr 24;94 (8):1130-5.
14. Iwase H, Shimada M, Tsuzuki T. et al: A phase I study of S-1 administration and a 24-h infusion of cisplatin
plus paclitaxel in patients with advanced gastric cancer. Anticancer Res. 2006 Mar-Apr; 26 (2B):1605-9.
15. Japanese Gastric Cancer Association Registration Committee; Maruyama K, Kaminishi M. et al:
Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006;9
(2):51-66.
16. Jenab M, Riboli E, Ferrari P. et al: Plasma and dietary vitamin C levels and risk of gastric cancer in
the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Carcinogenesis.
2006 Nov;27 (11):2250-7.
17. Kassam Z, Lockwood G, O’Brien C. et al: Conformal radiotherapy in the adjuvant treatment of gastric
cancer: Review of 82 cases. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65 (3):713-9.
18. Kobayashi M, Tsuburaya A, Nagata N. et al: A feasibility study of sequential paclitaxel and S-1
(PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric
Cancer. 2006;9 (2):114-9.
19. Koizumi W, Tanabe S, Higuchi K. et al: Optimal dose-finding study of bi-weekly paclitaxel in unresectable
advanced or recurrent gastric cancer. Anticancer Res. 2006 Sep-Oct; 26 (5B):3797-802.
20. Kosaka T, Usami K, Ueshige N. et al: Paraaortic lymph node dissection for gastric cancer in 244
consecutive cases. Hepatogastroenterology. 2006 Jul-Aug;53 (70):629-33.
21. Kubben FJ, Sier CF, Meijer MJ. et al: Clinical impact of MMP and TIMP gene polymorphisms in gastric
cancer. Br J Cancer 2006 Sep 18;95 (6):744-51.
22. Kubben FJ, Sier CF, van Dujjn W. et al: Matrix metalloproteinase-2 is a consistent prognostic factor in
gastric cancer. Br J Cancer. 2006 Apr 10;94 (7):1035-40.
23. Lee HS, Choi Y, Hur WJ. et al: Pilot study of postoperative adjuvant chemoradiation for advanced gastric
cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol. 2006 Jan
28;12 (4):603-7.
24. Macri A. Versaci A, Loddo S. et al: Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis
factor alpha as markers of gastric cancer. Biomarkers. 2006 Mar-Apr; 11 (2):184-93.
25. Mammano E, Belluco C, Sciro M. et al: Epidermal growth factor receptor (EGFR): mutational and protein
expression analysis in gastric cancer. Anticancer Res. 2006 Sep-Oct; 26 (5A):3547-50.
26. Marcenaro M, Foppiano F, Durzu S. et al: Kidney-sparing radiotherapy by multiple-field three-dimensional
technique in the postoperative management of patients with gastric cancer: comparison with standard
two-field conformal technique. Tumori. 2006 Jan-Feb;92 (1):34-40.
27. Milano MT, Garofalo MC, Chmura SJ. et al: Intensity-modulated radiation therapy in the treatment of
134 Gastro Update 2007
gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J
Radiol. 79 (2006), 497-503.
28. Murad AM, Skar NG. et al: Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF)
in the treatment of advanced gastric cancer: a novel, safe, and active regimen. Gastric Cancer. 2006;9
(2):99-105.
29. Murad AM, Skare NG, Vinholes J. et al: Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil
(DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen. Gastric Cancer.
2006;9 (2):99-105.
30. Nguyen S, Rebischung C, Van Ongeval J. et al: Epirubicin-docetaxel in gastric cancer: two phase II
studies as second and first line treatment Bull Cancer. 2006. Jan 1;93 (1):E1-6.
31. Papakostas P, Tsavdaridis D, Kosmidis P. et al: Combination docetaxel (Taxotere), fluorouracil, and
leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative
Oncology Group phase II study. Gastric Cancer. 2006;9 (1):26-31.
32. Park DI, Yun JW, Park JH. et al: HER-2/neu amplification is an inderpendent prognostic factor in gastric
cancer. Dig Dis Sci. 2006 Aug; 51 (8):1371-9.
33. Park SH, Lee WK, Chung M. et al: Paclitaxel versus docetaxel for advanced gastric cancer: a randomized
phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 2006 Feb;17 (2):225-9.
34. Park YH, Kim BS, Byoo BY. et al: A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line
therapy for patients with advanced gastric cancer. Br J Cancer. 2006 Apr 10;94 (7):959-63.
35. Polyzos A. Tsavaris N, Kosmas C. et al: Subsets of patients with advanced gastric cancer responding to
second-line chemoterapy with docetaxel-cisplatin. Anticancer Res. 2006 Sep-Oct;26 (5B):3749-53.
36. Rino Y, Takamashi Y, Yukawa N. et al: A phase I study of bi-weekly combination therapy with S-1 and
docetaxel for advanced or recurrent gastric cancer. Anticancer Res. 2006 Mar-Apr;26 (2B):1455-62.
37. Rohatgi PR, Mansfield PF, Crane CH. et al: Surgical pathology stage by American Joint Comission on
Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.
Cancer. 2006 Oct 1;107 (7):1475-82.
38. Rohatgi PR, Yao JC, Hess K. et al: Outcome of gastric cancer patients after successful gastrectomy:
influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 1;107 (11):2576-80.
39. Romano F, Cesana G, Caprotti R. et al: Preoperative IL-2 immunotherapy enhances tumor infiltrating
lymphocystes (TILs) in gastric cancer patients. Hepatogastroenterology. 2006 Jul-Aug;53 (70):634-8.
40. Roviello F, Rossi S, Marrelli D. et al: Number of lymph node metastases and its prognostic significance
in early gastric cancer: a multicenter Italian study. J Surg Oncol. 2006 Sep 15;94 (4):275-80.
41. Ruzzo A, Grazianoo F, Kawakami K. et al: Pharmacogenetic profiling and clinical outcome of patients with
advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol. 2006 Apr 20;24 (12):1883-91.
42. Sadighi S, Mohagheghi MA, Montazeri A. et al: Quality of life in patients with advanced gastric cancer:
a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
BMC Cancer. 2006 Dec 5;6:274.
43. Sakamoto J, Chin K, Kondo K. et al: Phase II study of a 4-week capecitabine regimen in advanced or
recurrent gastric cancer. Anticancer Drugs. 2006 Feb;17 (2):231-6.
44. Takahashi T, Saikawa Y, Yoshida M. et al: A pilot study of combination chemotherapy with S-1 and low-dose
cisplatin for highly advanced gastric cancer. Anticancer Res. 2006 Mar-Apr; 26 (2B):1631-5.
45. Tormo Ferrero V, Andrea Marinez FJ, Cardenal Macia R. et al: Evaluation of the toxicity of
chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed
of gastric cancer. Clin Transl Oncol. 2006 Aug; 8 (8):611-5.
46. Tentes AA, Markakidis SK, Karanikiotis C. et al: Intraarterial chemotherapy as an adjuvant treatment
in locally advanced gastric cancer. Langenbecks Arch Surg. 2006 Apr; 391 (2):124-9.
47. Ueda Y, Fujimura T, Kinami S.et al: A randomized phase III trial of postoperative adjuvant therapy with
A gyomor 135
S-1 alone versus s-1 plus PSK for stage II/IIIA gastric cancer. Hokuriku-Kinki Immunochemo-Therapy
Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol. 2006 Aug;36 (8):519-22.
48. Van Cutsem E, Moiseyenko VM, Tjulandin S. et al: Phase III study of docetaxel and cisplatin plus
fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:
a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24 (31):4991-7.
49. Wals A, Contreras J, Macias J. et al: Damage assessment in gastric cancer treatment with adjuvant
radiochemotherapy: calculation of the NTCP’s from the differential HDV of the organs at risk. Clin
Transl Oncol. 2006 Apr>8 (4):271-8.
50. Yamaguchi K, Shimamura T, Kometsu Y. et al: Phase I-II study of biweekly paclitaxel administration
with fixed-dose-rate cisplatin in advanced gastric cancer. Gastric Cancer. 2006;9 (1):36-43.
51. Yonemura Y, Bandou E. Sawa T. et al: Neoadjuvant treatment of gastric cancer with peritoneal
dissemination. Eur J Surg Oncol. 2006 Aug;32 (6):661-5.
52. Yoshida T, Yoshikawa T, Tsuburaya A. et al: Geasibility study of biweekly CPT-11 plus CDDP for S-1
and paclitaxel-refractory, metastatic gastric cancer. Anticancer Res. 2006 Mar-Apr;26 (2B):1595-8.
